NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

724.87

-7.33

(-1.00%)

At close: April 25 at 4:00 PM EDT

729.10

+4.23

(+0.58%)

Pre-Market: 4:44 AM EDT

Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?

Investor's Business Daily 16 hours ago

LLY
-1.00%
NVO
-0.29%
BIIB
+0.23%
20 Fastest Growing Health Tech Companies in the World

In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]

Insider Monkey 17 hours ago

TDOC

SNY

GSK
+0.12%
Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Zacks 19 hours ago

LLY
-1.00%
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.

Zacks 20 hours ago

NVO
-0.29%
LLY
-1.00%
ABBV
-0.30%
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Zacks yesterday

PFE
-3.84%
LLY
-1.00%
AMGN
-1.33%
4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Zacks yesterday

ABBV
-0.30%
LLY
-1.00%
NVO
-0.29%
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

PFE
-3.84%
LLY
-1.00%
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Zacks yesterday

LLY
-1.00%
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks yesterday

LLY
-1.00%
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug Market

Lilly recently announced news that could solve a big problem.

Motley Fool yesterday

LLY
-1.00%
14 Dividend Growth Stocks with Highest Growth Rates

In this article, we discuss 14 dividend growth stocks with highest growth rates. You can skip our detailed analysis of dividend growth stocks and their overall performance, and go directly to read 5 Dividend Growth Stocks with Highest Growth Rates. According to a report by ProShares, the S&P 500 Dividend Aristocrats Index, which tracks the […]

Insider Monkey 2 days ago

^GSPC

GSC

LLY
-1.00%
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

LLY
-1.00%
ABBV
-0.30%
Eli Lilly and Company (LLY) Rose due to Robust Q4 Sales

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

Insider Monkey 2 days ago

LLY
-1.00%
^GSPC
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.

Zacks 3 days ago

LLY
-1.00%
Lilly to buy injectable drug plant in manufacturing ramp-up

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

BioPharma Dive 3 days ago

LLY
-1.00%
NVO
-0.29%
Eli Lilly to acquire manufacturing facility from Nexus Pharma

Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines. Lilly expects production at the facility based in Pleasant Prairie, Wisconsin, to begin at the end of 2025. Soaring demand for GLP-1 agonists, a class of highly effective diabetes and obesity drugs which suppress appetite and promote a feeling of fullness, has led to constrained supply for drugmakers such as Lilly and Danish drugmaker Novo Nordisk .

Reuters 3 days ago

LLY
-1.00%
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]

Insider Monkey 3 days ago

LLY
-1.00%
EXAS

NBIX
11 Hot Growth Stocks To Buy Right Now

In this article, we discuss the 11 hot growth stocks to buy now. If you want to read about some more growth stocks that are active in the market, go directly to the 5 Hot Growth Stocks To Buy Right Now. As 2024 moves forward, the outlook for both the stock and bond markets undergoes […]

Insider Monkey 4 days ago

PLTR

SHOP

LLY
-1.00%
10 Best Healthcare Stocks to Buy Under $20

In this article, we will be taking a look at the 10 best healthcare stocks to buy under $20. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks to Buy Under $20. Global Healthcare Outlook for 2024 As 2024 progresses, the optimism surrounding the healthcare […]

Insider Monkey 5 days ago

RCM

NVST

OSCR
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

Motley Fool 5 days ago

LLY
-1.00%
NVO
-0.29%

Performance Overview

Return	LLY	S&P 500
YTD	+24.57%	+5.84%
1-Year	+90.67%	+22.03%
3-Year	+298.18%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Company (LLY)

Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

20 Fastest Growing Health Tech Companies in the World

Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug Market

14 Dividend Growth Stocks with Highest Growth Rates

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Eli Lilly and Company (LLY) Rose due to Robust Q4 Sales

Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

Lilly to buy injectable drug plant in manufacturing ramp-up

Eli Lilly to acquire manufacturing facility from Nexus Pharma

10 Best Performing Biotech ETFs in 2024

11 Hot Growth Stocks To Buy Right Now

10 Best Healthcare Stocks to Buy Under $20

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Performance Overview